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Thymocyte Development
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DR3 (Ws1, Apo3, LARD, TRAMP, TNFSFR12) is a member of the death domain-containing tumor necrosis
factor receptor (TNFR) superfamily, members of which mediate a variety of developmental events including the
regulation of cell proliferation, differentiation, and apoptosis. We have investigated the in vivo role(s) of DR3
by generating mice congenitally deficient in the expression of the DR3 gene. We show that negative selection
and anti-CD3-induced apoptosis are significantly impaired in DR3-null mice. In contrast, both superantigen-
induced negative selection and positive selection are normal. The pre-T-cell receptor-mediated checkpoint,
which is dependent on TNFR signaling, is also unaffected in DR3-deficient mice. These data reveal a nonre-
dundant in vivo role for this TNF receptor family member in the removal of self-reactive T cells in the thymus.
The tumor necrosis factor receptor (TNFR) superfamily
comprise a growing family of type I membrane bound glyco-
proteins which interact with the TNF family of soluble medi-
ators and type II transmembrane proteins. At least 23 TNFR
superfamily members and 17 known ligands have been identi-
fied in mammals (reviewed in references 3, 35, and 44). These
receptors trigger pleiotropic responses, ranging from apoptosis
and differentiation to proliferation, and have been implicated
in immune regulation, host defense and lymphoid organ de-
velopment.
Members of the TNFR family are characterized by the pres-
ence of varying numbers (three to six) of cysteine-rich repeats
in their cytoplasmic domains (52). TNFRs are subdivided
based on the presence or absence of a 70- to 80-amino-acid
region of homology in the cytoplasmic region called the death
domain, through which these receptors trigger apoptosis (20,
48). DR3 (also called Ws1, Apo3, TRAMP, LARD, TR3, and
TNFRSF12) is one of six death domain-containing TNFR fam-
ily members (the others are TNFR1, CD95/FAS, DR4, DR5,
and DR6) and is the one most closely related to TNFR1.
Studies on the TNFR1 crystal structure suggest that ligand
binding or receptor overexpression results in receptor trimer-
ization and recruitment of trimeric intracellular signaling mol-
ecules (4, 36). DR3, like TNFR1, recruits TNFR1-associated
death domain protein (TRADD) and Fas-associated death
domain-containing protein (FADD) (5, 6, 11, 12, 24) as down-
stream effectors of apoptosis. These, in turn, interact with
caspase 8 (FLICE/MACH) (7, 31), and a cascade of interleu-
kin-1b-converting enzyme-like cysteine proteases which trigger
cell death (13, 17, 27). DR3 also recruits TRAF2 via TRADD
(18, 24, 29, 39) and thus activates the transcription factor,
NF-kB, that induces the transcription of a number of immune
genes (19). In this respect, DR3 (like TNFR1) is capable of
inducing both apoptosis and expression of survival/activation
genes and is likely to have multiple functions depending on the
context of its expression.
DR3 was first reported as the only death domain-containing
TNFR family member with lymphoid organ-restricted expres-
sion (11, 24). More recent studies have, however, shown DR3
expression to be less restricted, though not as ubiquitous ex-
pression of as its other death domain-containing TNFR rela-
tives (47, 51). DR3 expression patterns may be further com-
plicated by the presence of at least 13 human (24, 42, 53) and
3 mouse (51) splice variants. DR3 splicing may be develop-
mentally regulated since human peripheral blood leukocytes
have been shown to express full-length DR3 mRNA only fol-
lowing activation (42). While the ligand for DR3 has been
reported as TWEAK (30, 10), it has also been shown that
TWEAK can bind and signal in a DR3-negative cell line via
a TNF/TNFR1-related mechanism (40). Thus, the problems
with identifying a single ligand together with the complex ex-
pression of DR3 have contributed to the lack of functional data
for this gene. To date, the only ex vivo indication, albeit indi-
rect, that DR3 has an apoptotic role stems from the detection
of translocations affecting the DR3 gene in several neuroblas-
toma cell lines (16).
To determine the in vivo function(s) of DR3, we generated
mice that are deficient in the expression of its murine homo-
logue. DR3-deficient mice show no defects in organ develop-
ment (lymphoid or otherwise), lymphoid proliferation, or ap-
optosis triggered by glucocorticoids or DNA-damaging agents.
There is also no defect in the progression of double-negative
(DN) thymocytes through the pre-T-cell receptor (TCR)-me-
diated checkpoint, a developmental transition at which TNFR
signaling has been shown to be important (33). However, an
impairment of negative selection, as well as anti-CD3-medi-
ated cell death of thymocytes, is observed in DR3-deficient
mice, suggesting a nonredundant role in TCR-induced apopto-
sis that establishes central tolerance in vivo.
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MATERIALS AND METHODS
Generation of DR32/2 mice. A human cDNA corresponding to the full-length
DR3 gene was used as a probe to isolate clones from an EMBL3A phage library
of 129/Sv mouse strain genomic DNA (51). A 6-kb SmaI-MfeI fragment covering
the whole of the coding region of the DR3 gene was replaced with a cassette
containing an internal ribosome entry site (IRES), lacZ poly(A), and neomycin
resistance (neo) gene flanked by loxP sequences (a gift from Andrew Smith,
University of Edinburgh, Edinburgh, United Kingdom). The DR3 gene targeting
construct was linearized and transfected into GK129 embryonic stem (ES) cells
by electroporation. ES cell clones were selected in G418-containing medium on
a monolayer of mitotically inactivated STO feeder cells. Clones were picked and
screened for homologous recombinants using the probes shown in Fig. 1A. ES
clones with correct 59 and 39 recombinations were microinjected into C57BL/6
blastocysts and introduced into pseudopregnant C57BL/6 mice. Male chimeric
offspring were bred to obtain germ line mutant mice which were screened either
by Southern blotting or by PCR.
Maintenance and breeding of mouse strains. All mice were kept under barrier
conditions at the Imperial Cancer Research Fund animal unit. H-Y TCR trans-
genic mice were kindly provided by H. von Boehmer (22). Rag 12/2 mice were
acquired from the Jackson Laboratory. For H-Y TCR transgenic studies,
DR32/2 3 H-Y TCR mice were obtained by crossing DR32/2 mice with
DR31/2 H-Y TCR heterozygote transgenics, thus deriving DR31/2 and DR32/2
mice with and without the H-Y TCR transgene. All mice analyzed were between
6 and 14 weeks of age. For analysis of each age group (6, 10, and 14 weeks), mice
were sacrificed within one day of their weekly age.
Flow cytometric analysis. Fluorescence-activated cell sorting (FACS) analysis
was performed on a FACScan (Becton Dickinson) using CellQuest software.
Single-cell suspensions were prepared from freshly isolated bone marrow, lymph
nodes (inguinal), spleen, and thymus. All samples were gated on standard for-
ward scatter versus-side scatter gates. Thymocytes were stained using combina-
tions of the antibodies from Becton Dickinson (anti-CD4-fluorescein isothiocya-
nate [FITC], anti-CD4-phycoerythrin [PE], anti-CD8-FITC, anti-CD8-biotin,
anti-CD30, anti-CD44-PE, anti-CD25-biotin, anti-Vb8-FITC [F23.1], anti-CD3-
FITC [2C11], anti-abTCR-FITC, anti-gdTCR-FITC, anti-B220-FITC, and anti-
5-bromo-29-deoxyuridine [BrdU]) or Caltag Laboratories (anti-CD8-Tricolor,
streptavidin-Tricolor, anti-neutrophil-FITC, and anti-monocyte-FITC) or kindly
donated by P. Kieselow and H. von Boehmer for H-Y transgenic analysis (T3.70
and T3.70-FITC specific for Va3 [49]). BrdU and unconjugated T3.70 or CD30
were visualized using anti-mouse immunoglobulin G (IgG)-FITC (Dako).
Lymphocyte proliferation assays. In vivo BrdU incorporation assays were
carried out as described elsewhere (56). In brief, 1 mg of BrdU (Sigma) was
injected twice intraperitoneally, 30 min apart. Mice were then sacrificed after 6 h,
thymuses were extracted, and single-cell-suspension thymocytes were isolated.
BrdU incorporation was visualized using a standard BrdU-labeling protocol (28)
with an anti-BrdU antibody (Becton Dickinson) and anti-mouse Ig-FITC sec-
ondary (Dako) and analyzed on a FACScan (Becton Dickinson).
For in vitro [3H]thymidine uptake assays, 2 3 105 lymphocytes, isolated as
described above, were aliquoted into 96-well flat-bottomed plates and stimulated
with anti-CD3 (2C11), anti-CD3, and anti-CD28 (37.51; Pharmingen), 1 ng of
phorbol myristate acetate (PMA) and ionomycin (Sigma) per ml, or 5 mg of
concanavalin A (Sigma) per ml. For antibody stimulations, plates were previously
coated with the monoclonal antibodies (MAbs) overnight at 4°C at 10 mg/ml in
phosphate-buffered saline (PBS) and washed five times with PBS before use.
Cultures were performed in RPMI medium supplemented with 10% heat-inac-
tivated fetal calf serum and 50 mM b-mercaptoethanol. Stimulations were carried
out in triplicate and incubated for 72 h before pulsing for 18 to 24 h with
[3H]thymidine (1 mCi/well; Dupont NEN, Boston, Mass.). Cells were then har-
vested onto fiberglass filter mats (Pharmacia, Uppsala, Sweden) and washed with
a cell harvester (Skatron). Beta emission was counted on a Betaplate counter
(Pharmacia). Results are presented as a stimulation index, calculated as the
geometric mean of stimulated cultures/geometric mean of control cultures with
medium only 6 1 standard deviation. No significant differences were observed
between the medium-only controls of DR31/2 and DR32/2 lymphocytes.
Apoptosis assays. For anti-CD3-induced apoptosis assays, experiments were
carried out as described elsewhere (46). In brief, 96-well flat-bottomed plates
were coated with anti-CD3 MAb 2C11 (2, 10, or 50 mg/ml) or anti-CD3 and
anti-CD28 MAb (each at 10 mg/ml) in PBS, overnight at 4°C, or with rat Ig as a
control. Plates were washed three times with PBS before use. Thymocytes were
extracted, resuspended in single-cell suspension in Dulbecco’s modified Eagle’s
medium (Gibco BRL) supplemented with 10% heat-inactivated fetal calf serum,
and aliquoted into plates at 5 3 105 cells/well. For PMA (Sigma) stimulation, a
final concentration of 1 ng/nl was used. Samples were then incubated at 37°C for
the indicated times before analysis for apoptosing cells using annexin V-FITC
(Pharmingen) and propidium iodide staining to gate out dead cells. All samples
were performed in triplicate. Values for percent anti-CD3-induced apoptosis
were calculated using the following formula: (% annexin V1 cells after anti-
CD3 2 % annexin V1 cells in rat Ig controls)/(100 2 % annexin V1 cells in rat
Ig controls) 3 100. For other apoptosis assays, thymocytes were cultured in vitro
in standard RPMI medium supplemented with 10% heat-inactivated fetal calf
serum and 50 mM b-mercaptoethanol, and apoptosis was induced by stimulation
with the following reagents: cycloheximide (30 mg/ml) and anti-Fas antibody (1
mg/ml); dexamethasone (2 mM); and etoposide (50 mM). Samples were taken at
4, 8, 12, 24, and 48 h poststimulation. Apoptosis was visualized using both
annexin V-FITC staining, or pre-G1 peak DNA staining with propidium iodide.
RESULTS
Generation of DR32/2 mice. The strategy used to inactivate
the DR3 gene in ES cells is shown in Fig. 1A. We chose to
disrupt exon 1 and replace all of the coding exons of the gene
to exclude the possibility of any expression of DR3 splice
variants. The entire coding region of the DR3 gene, from exon
1 (56 bp upstream of the ATG initiation codon) to 297 bp
downstream of the polyadenylation site, was replaced with a
construct containing an IRES, b-galactosidase (lacZ) gene,
and neo gene flanked by laxP sites. ES cell clones with correct
59 and 39 recombinations were detected by screening using
probes outside the recombination arms of the targeting vector.
59 recombination was detected by the reduction of a 6.5-kb
wild-type BamHI fragment to 3.9 kb and 39 recombination by
the reduction of an 11.5-kb wild-type XbaI band to 10 kb (Fig.
1A and B). The homologous recombination frequency was
4.2%. Four clones were chosen for injection into blastocysts.
Mice heterozygous for the targeted allele, as detected by
screening for 59 recombination in genomic Southern blots of
tail DNA (Fig. 1C), were generated from two ES cell clones
with correct 59 and 39 integrations of the targeting construct.
Breeding of heterozygous (DR31/2) mice generated ho-
mozygote DR3-null (DR32/2) mice (Fig. 1C) in normal Men-
delian and male/female ratios (data not shown). Due to the
targeting strategy (deletion of the entire coding region of the
DR3 gene), the mutation must clearly be null. In agreement
with this, no transcripts were detected by PCR analysis using
any combination of primers specific for the DR3 coding se-
quence. A representative reverse transcription-PCR demon-
strating this using primers encoding sequences within the DR3
death domain is shown in Fig. 1D.
Normal development of major organs, peripheral lymphoid
organs, and lymphocyte subsets in DR32/2 mice. The pattern
of expression of mouse DR3 in the brain, heart, and kidney as
well as lymphoid organs (51) prompted us to investigate
whether there were any general developmental defects in
DR32/2 mice. Histological analysis of all major organs (includ-
ing brain, heart, and kidney) revealed no abnormalities (data
not shown). In particular, the peripheral lymphoid organs such
as thymus, spleen, lymph nodes, and Peyer’s patches all showed
normal development. Primary B-cell follicles and follicular
dendritic cell networks were present in the peripheral lym-
phoid organs from DR32/2 mice (data not shown), unlike their
TNFR12/2 counterparts (25, 32, 37).
A more detailed analysis of the B- and T-lymphocyte pop-
ulations in peripheral lymphoid organs from DR3-deficient
mice was carried out by FACS analysis using a battery of
antibodies that define the various lymphoid populations. No
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FIG. 1. Generation and screening of DR32/2 mice. (A) Map of the coding region of the DR3 gene (top), the targeting construct (middle), and
the targeted locus (bottom). Restriction enzyme sites are indicated by single letters; B, BamHI; E, EcoRI; H, HindIII; M, MfeI; S, SmaI; X, XbaI.
The positions of the DR3 exons are shown. An IRES/lacZ/loxP/neo vector was used to replace the whole coding region of the DR3 gene. The 59
arm was generated using a 3-kb HindIII-SmaI fragment, while the 39 arm consisted of a 3-kb MfeI-EcoRI fragment. (B) Southern blot screening
for homologous recombination in ES cell clones. Genomic DNA was isolated from transfected ES cell clones, digested with either BamHI or XbaI,
and screened with probe A (left) for 59 recombination or probe B (right) for 39 recombination, respectively. Only ES cell clones with correct
recombination at both ends were used for injections. Sizes of fragments are indicated. (C) Southern blot analysis and genomic PCR of
representative mouse tail DNA. Genomic DNA was isolated from mouse tails, screened for correct 59 recombination by Southern blotting using
a BamHI digest and probe A, and screened for correct 39 recombination by genomic PCR using the three primers (filled triangles) F1, F2 (in the
neo gene), and R1. Sizes of fragments, recombinant and wild-type bands are indicated. (D) Reverse transcription-PCR analysis of thymus cDNA.
cDNA prepared from total thymus RNA was subjected to PCR analysis using specific primers corresponding to sequences within the DR3 death
domain exon. Actin primers were used a positive control. Sizes of fragments are indicated.
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significant differences were observed between DR32/2 mice
and their heterozygous or wild-type littermates (data not
shown). There were also no significant differences in the weight
and size of spleens or lymph nodes at any age examined (data
not shown).
Increased thymus size but normal turnover in DR32/2 mice.
TNFR family members have been shown to be important reg-
ulators of developmental processes. The expression of DR3 in
developing thymocytes suggested that DR3 may be a regulator
of thymocyte development. To determine whether DR3 is re-
quired for normal thymocyte development, thymocyte sub-
populations were analyzed by flow cytometry. There were no
significant differences in the four major thymocyte populations
defined by the expression of the CD4 and CD8 markers. How-
ever, a small but significant increase in the average total num-
ber of thymocytes derived from DR3-deficient mice, compared
to heterozygous littermates, was observed (Fig. 2A). At 2 to 5
weeks of age, DR32/2 thymuses were generally about 10%
larger than their heterozygote counterparts, and by 29 to 32
weeks this difference had increased to about 30%. A larger
study (data not shown), covering mice aged from 26 to 233
days, showed these differences to be significant using a differ-
ent statistical analysis (Mann-Whitney U test; U 5 5,965, P ,
0.05). No difference in thymocyte number was observed be-
tween wild-type and heterozygous mice (data not shown). This
increase in thymus size appeared not to be a consequence of an
increase in thymocyte proliferation and/or turnover, since nei-
ther the proportion nor the numbers of thymocytes which
incorporated BrdU differed significantly between DR32/2 and
DR31/2 mice (Fig. 2B).
Early thymocyte development is unaffected by the absence of
DR3. The small but significant increase in total thymocyte
numbers in DR3-deficient mice was consistent with a regula-
tory role of DR3 at one or more stages of thymocyte develop-
ment. There are two major checkpoints at which thymocyte
development is controlled. The DN-to-double-positive (DP)
thymocyte transition selects immature thymocytes with in-
frame TCRb rearrangements and is regulated by the pre-TCR.
The DP-to-single-positive (SP) thymocyte transition selects
major histocompatibility complex (MHC)-restricted, nonauto-
reactive thymocytes and is regulated by the mature abTCR. To
investigate whether DR3 plays an essential role in early thy-
mocyte development, we initially analyzed DN thymocyte sub-
sets, as defined by the absence of CD4, CD8, abTCR, gdTCR,
and B220 surface markers and the differential expression of
CD44 and CD25, by flow cytometry. As shown in Fig. 2C
(upper panels), this analysis revealed no consistent differences
in the relative proportions of DN populations in DR32/2 com-
pared to DR31/2 mice.
Analysis of transgenic mice expressing dominant negative
FADD (DN-FADD)/MORT1 (which binds to TNFR death
domains) has implicated a role for death receptor signaling in
early thymocyte development at the pre-TCR checkpoint (33).
This study showed that the DN-FADD transgene bypassed the
requirement for pre-TCR signaling, promoting the survival
and differentiation, but not the proliferation, of CD251
CD442 thymocytes in Rag-deficient mice. These results have
suggested a model in which dual signaling, via the pre-TCR
and death receptors, triggers the development of early pre-T
cells, whereas death receptor signaling in thymocytes that lack
a pre-TCR induces apoptosis. To test whether FADD recruit-
ment to DR3 is essential for the regulation of the pre-TCR-
mediated checkpoint, Rag1 3 DR3 doubly deficient mice were
analyzed. As shown in Fig. 2C (lower panels), thymocyte de-
velopment was completely arrested at the CD251 CD442 DN
stage in Rag2/2 3 DR32/2 mice, demonstrating that DR3 is
not essential for FADD-mediated deletion of DN thymocytes
that fail to make in-frame rearrangements at the TCRb locus.
Negative selection is impaired in DR32/2, H-Y transgenic
mice. The DP-to-SP thymocyte transition is a checkpoint at
which a developmental decision is made between cell death
and survival. Thymocytes expressing abTCRs that have no
detectable affinity for ligand, or which are autoreactive, un-
dergo apoptosis, whereas cells expressing abTCRs with inter-
mediate affinities receive survival signals and generate the pool
of mature SP thymocytes and abT cells. To investigate whether
DR3 is essential for efficient negative selection of thymocytes,
the H-Y TCR transgenic mouse model was used (22). The H-Y
TCR recognizes a male-specific antigen in the context of H-2b
In male mice, thymocytes expressing the transgenic TCR are
deleted, whereas in female mice, transgene-expressing cells
undergo positive selection, resulting in an increased propor-
tion of CD8 SP cells.
In male H-Y TCR H-2b transgenic mice, CD81 TCR-ex-
pressing cells are efficiently deleted by negative selection. To
determine whether this deletion was dependent on the expres-
sion of DR3, the proportion of CD81 TCR-expressing thymo-
cytes from DR3-deficient, H-Y TCR male mice was analyzed
by flow cytometry using MAb T3.70, which recognizes the Va3
chain of the H-Y TCR. This analysis was carried out using
male mice 6, 10, and 14 weeks of age. As shown in Fig. 3A and
B, and as reported previously (22), an age-dependent deletion
of transgenic TCR-positive, CD81 thymocytes was observed in
male mice. At 14 weeks of age, the total numbers and propor-
tion of H-Y TCR CD8 SP thymocytes were barely detectable.
A striking increase in the numbers and proportions of CD81
T3.701 thymocytes, was observed in DR3-deficient H-Y TCR
transgenic male mice compared to DR31/2 littermates. A sig-
nificant difference was apparent in 10-week-old male mice and,
by 14 weeks of age there was at least a fourfold difference in
the numbers of transgenic TCR-positive CD81 SP cells in
DR3-deficient male mice.
The observed increase in the numbers of CD81 T3.701
thymocytes could be a consequence of either an increase in
proliferation and/or a decrease in apoptosis of this subset. To
distinguish between these possibilities, the turnover of thymo-
cytes in male DR32/2 H-Y and DR31/2 H-Y TCR transgenic
littermates was investigated by examining their BrdU incorpo-
ration. Mice 10 weeks age were chosen, as no significant dif-
ferences in CD81 T3.701 thymocyte numbers or thymus size
were observed at 6 weeks (Fig. 3B and data not shown), while
at 14 weeks around half the DR31/2 H-Y mice had virtually
undetectable thymuses. The proportion of thymocytes incor-
porating BrdU into DNA did not differ in the DR31/2 or
DR32/2 background, but as expected from the increase in
thymus size, there was a significant increase in the numbers of
BrdU1 thymocytes in DR32/2 H-Y male mice (Fig. 3C). Sig-
nificantly, the numbers of transgenic Vb81 thymocytes were
increased and accounted for the rise in observed BrdU uptake
(Fig. 3C).
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One means by which thymocytes escape negative selection in
male H-Y transgenic mice is by down-regulation of the CD8
coreceptor, allowing a small proportion of T3.701 transgenic
thymocytes to migrate to the periphery (22). Thus, CD8lo
T3.701 T cells can be detected in the peripheral lymphoid
organs, though these cells remain unresponsive to H-Y antigen
due to undefined peripheral tolerance mechanisms. Increased
down-regulation of the CD8 coreceptor may therefore be one
possible mechanism for the defect in negative selection that is
observed in DR32/2 H-Y TCR transgenic mice. However, as
shown in Fig. 3A and D, there was an increased proportion of
CD81 T3.701 thymocytes in male DR32/2 mice compared to
their heterozygous littermates, demonstrating that coreceptor
down-regulation is not the major mechanism of escape from
negative selection in these mice. A reduction in the surface
level of the H-Y TCR may also enable thymocytes to escape
negative selection. However, as shown in Fig. 3D, surface H-Y
TCR levels were equivalent in DR32/2 and DR31/2 mice.
Defective negative selection in male H-Y TCR transgenic
DR32/2 mice might be expected to result in an equivalent
increase in the CD81 T3.701 T-cell load in the peripheral
lymphoid organs. To test this possibility, the number of trans-
genic peripheral T cells was determined. As no differences in
the development of different lymph nodes were observed in
DR32/2 mice (data not shown), inguinal lymph nodes from
H-Y TCR transgenic mice were used as a representative lymph
node. While no differences were detected in inguinal lymph
nodes, a significant increase (;40%) in the numbers of CD81
T3.701 T cells was observed in the spleens of DR32/2 mice.
A previous analysis has revealed that mice deficient in the
expression of CD30, a TNFR family member that lacks a death
domain, exhibit defective negative selection (2). Since CD30
maps to the same chromosomal location as DR3 (8), it is
possible that the observed negative selection defect in DR3-
null mice is a consequence of an indirect effect of the gene
targeting strategy on CD30 gene expression. To rule out this
possibility, CD30 expression on thymocytes from DR32/2 mice
was assayed by flow cytometry. There were no differences in
the overall proportions of CD30-expressing thymocytes be-
tween DR32/2 thymocytes and their heterozygous or wild-type
littermates. However, a more detailed analysis identified a
CD4lo CD8lo CD301 population that was significantly reduced
in DR32/2 mice compared to their DR31/2 counterparts (data
not shown). The reduction in this thymocyte subset is age
dependent, but CD4lo CD8lo CD301 cells were generally lower
in both proportion and number in DR32/2 mice. There were
no significant differences in this subset between DR31/2 and
DR31/1 mice (data not shown).
Endogenous superantigen-mediated deletion of T cells is
unaffected in DR3-deficient mice. T cells expressing TCRs that
recognize minor lymphocyte-stimulating determinants en-
FIG. 2. Analysis of thymocyte development in DR31/2 and
DR32/2 mice. (A) Thymus size in DR32/2 mice. Total thymocyte
numbers were collected for mice at the ages indicated (DR31/2 and
DR32/2, n $ 11 and n $ 10, respectively, for each age group), and
means were generated. DR32/2 thymuses were generally larger than
their DR32/2 counterparts, irrespective of age. Significance using t
tests is indicated. (B) Turnover and proliferation in DR32/2 thymus.
The proportion (left) and number (right) of BrdU1 thymocytes were
estimated as described in Materials and Methods. Filled bars, DR32/2;
hatched bars, DR31/2. (C) Early thymocyte development in DR32/2
mice. Upper panels depict representative FACS plots showing expres-
sion of CD44 and CD25 in early thymocyte subsets from DR31/2 (left)
and DR32/2 (right) mice. Thymocytes were extracted and depleted of
cells expressing CD4 and CD8 using specific antibodies and comple-
ment. The remaining thymocytes were stained with anti-CD44-PE,
anti-CD25-biotin with streptavidin-Tricolor and anti-CD4-FITC, anti-
CD8-FITC, anti-B220-FITC, gdTCR-FITC, and abTCR-FITC. DN
thymocytes were analyzed by gating on the CD42, CD82, B2202,
abTCR2, and gdTCR2 populations. Lower panels depict representa-
tive FACS plots showing CD4 and CD8 thymocyte subsets in Rag-1-
deficient DR31/2 (left) and DR32/2 (right) mice.
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FIG. 3. Negative selection in male DR32/2 3 H-Y transgenic mice. (A) Representative FACS plots showing expression of CD8 and T3.70 in
14-week-old male H-Y transgenic mice. Thymocytes were extracted and stained with anti-CD4-PE, anti-CD8-Tricolor, and anti-T3.70-FITC.
DR32/2 3 H-Y mice (right) showed an increase in the proportions of CD81 T3.701 thymocytes compared to their DR31/2 3 H-Y littermates.
(B) Proportions and numbers of CD81 T3.701 thymocytes in H-Y TCR transgenic DR32/2 and DR31/2 mice with age. Male DR32/2 3 H-Y mice
showed higher proportions (top) and numbers (bottom) of CD81 T3.701 thymocytes with age compared to their DR31/2 3 H-Y littermates.
Differences were statistically significant using parametric (for numbers) or nonparametric (for percentages) t tests from 10 weeks of age and are
indicated on the graphs. Means were calculated from n $ 7 mice. Standard deviations of the means are indicated by bars. Filled bars, DR32/2;
hatched bars, DR31/2. (C) BrdU uptake of male DR32/2 3 H-Y transgenic mice, determined as described in Materials and Methods. The mean
from n $ 5 mice for each thymocyte population is shown. All mice were 10 weeks of age (61 day). Proportions (top) of BrdU1 thymocytes did
not differ between H-Y transgenic, DR32/2 and DR31/2 mice, but numbers (bottom) of BrdU1 thymocytes were increased in DR32/2 3 H-Y mice
compared to their DR31/2 littermates at 10 weeks of age. Increased numbers of total BrdU1 cells were due to increases in the BrdU1 DN and
transgenic Vb81 thymocyte populations. Filled bars, DR32/2; hatched bars, DR31/2. (D) CD8 and T3.70 expression on DR32/2 3 H-Y transgenic
thymocytes. Thymocytes were extracted from 10-week-old mice and stained with anti-CD4-PE, anti-CD8-Tricolor, and anti-T3.70-FITC. Thymo-
cytes were either gated for CD8 expression and their T3.70 expression (top) or gated for high T3.70 expression and their CD8 expression shown
(bottom). Representative overlay histograms are displayed and labeled with the proportion of positive cells and the level of each surface marker,
as measured by their mean fluorescence channel (MFC). Male DR32/2 3 H-Y mice (thick line) showed an increase in the proportion of T3.70hi
thymocytes expressing CD8 compared to their DR31/2 3 H-Y (shaded) littermates but no difference in the level of CD8 expression (lower panel).
There was no significant difference in the proportion of CD81 thymocytes expressing T3.70 or the level of T370 expression on CD81 thymocytes
compared with male DR32/2 and DR31/2 H-Y transgenic mice.
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coded by endogenous superantigens in the mouse genome
together with MHC class II molecules are deleted. Minor lym-
phocyte-stimulating determinants expressed on the 129 3
C57BL/6 background of DR3-deficient mice result in the de-
letion of several Vb-expressing CD41 T cells including Vb5
(1). To determine whether endogenous superantigen-driven
deletion is defective in DR3-null mice, lymph node T cells,
splenic T cells, and SP thymocytes were analyzed using anti-
bodies to specific Vb families. As shown in Table 1, Vb5-
bearing CD41 T cells were efficiently deleted in DR3-null
mice, whereas the proportion of nondeleting Vb8 cells was
unaffected. These data show that DR3 is not essential for
superantigen-mediated deletion.
Anti-CD3-induced, but not non-antigen receptor-mediated,
apoptosis is impaired in DR3-deficient mice. Immature DP
thymocytes and T cells are susceptible to an array of cell
death-inducing stimuli, including anti-CD3 cross-linking, glu-
cocorticoid treatment, Fas ligation, and DNA-damaging
agents. To assess whether these forms of apoptosis are also
dependent on DR3 expression, thymocytes and peripheral T
cells were subjected to treatment with anti-CD3 cross-linking,
the steroid dexamethasone, the DNA-damaging agent etopo-
side, and the protein synthesis inhibitor cycloheximide in con-
junction with an anti-Fas signal.
Using propidium iodide to exclude all dead cells and annexin
V surface labeling, the proportion of live thymocytes undergo-
ing early stages of apoptosis was measured at different time
points up to 48 h after stimulation. Cross-linking of surface
CD3 on DR32/2 thymocytes resulted in significantly reduced
levels of apoptosis compared to DR31/2 thymocytes at lower
concentrations of anti-CD3 MAb (2 mg/ml [Fig. 4A and B] and
10 mg/ml [data not shown]) but not higher concentrations (50
mg/ml) of coating anti-CD3 MAb (data not shown). The re-
duction in the proportion of apoptosing cells induced by anti-
CD3 treatment was observed at 12 h (data not shown) 24 and
48 h (Fig. 4B) and ranged from 15 to 45%. In contrast, the
levels of apoptosis of thymocytes induced by PMA or anti-CD3
and anti-CD28 (Fig. 4B) were indistinguishable between
DR31/2 and DR32/2 thymocytes.
In contrast, neither DR32/2 thymocytes nor lymphocytes
extracted from inguinal lymph nodes were resistant to any of
the other apoptosis-inducing agents used. There were no dif-
ferences in the rate of apoptosis over 48 h following treatment
with these agents compared to lymphocytes from DR31/1 and
DR31/2 mice (Fig. 5).
We extended these investigations by performing prolifera-
tion assays using a variety of polyclonal stimulators. Previous
studies have shown that lymphocytes from transgenic mice
expressing a dominant negative form of FADD, a downstream
signaling molecule of DR3, have impaired proliferative ability
(34, 56). Therefore, the ability of DR3-deficient thymocytes
and T cells to respond to a variety of proliferative stimuli was
assessed. DR32/2 lymph node cells, splenocytes, and thymo-
cytes exhibited no impairments in proliferation to anti-CD3,
anti-CD3, and anti-CD28, concanavalin A, or PMA plus iono-
FIG. 4. Apoptosis of thymocytes following CD3 ligation. (A) Rep-
resentative FACS histograms showing reduced proportions of annexin
V-positive thymocytes from DR32/2 mice compared to DR31/1 age-
and sex-matched controls after CD3 cross-linking. A stimulation of 2
mg/ml was used, and thymocytes were stained after 48 h. Dead cells
were gated out using propidium iodide. (B) Thymocyte suspensions
were stimulated for up to 48 h with plate bound anti-CD3 or rat Ig as
a negative control. Percent apoptosis was measured as the proportion
of propidium iodide-negative thymocytes, which were positive for an-
nexin V. Anti-CD3 treatment at 2 mg/ml resulted in an increase of
50.7% in apoptosing thymocytes above rat Ig controls by 48 h in
DR31/2 thymocytes (filled squares) compared to 38.7% in DR32/2
thymocytes (open squares). There were no differences in apoptosis of
DR32/2 (open) and DR31/1 (filled) thymocytes following stimulation
with PMA (triangles) or anti-CD3 and anti-CD28 (circles). Results are
the means of 3 DR32/2 and DR31/2 littermates, with duplicate cul-
tures performed on each mouse. Standard deviations are shown as
bars. p and pp represent P , 0.0003 and P , 0.004, respectively, using
t tests assuming unequal variance.
TABLE 1. MMTV superantigen deletion of CD4 and CD8 SP cells
SP cell type
Thymus Spleen Lymph node
Vb5 Vb8 Vb5 Vb8 Vb5 Vb8
CD4
DR31/1 3.0 6 0.4 15.0 6 1.3 2.7 6 0.6 17.5 6 1.8 2.2 6 0.3 19.0 6 0.8
DR32/2 3.2 6 0.9 13.7 6 1.3 2.5 6 0.3 17.3 6 1.5 2.2 6 0.1 18.5 6 0.2
CD8
DR31/1 10.7 6 0.9 9.9 6 1.3 12.4 6 0.6 17.9 6 1.2 13.3 6 0.8 16.0 6 1.5
DR32/2 11.0 6 4.1 7.4 6 1.1 14.8 6 2.0 19.7 6 3.7 13.0 6 0.3 16.6 6 1.7
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mycin compared to heterozygote or wild-type littermates
(Fig. 6).
Positive selection is unimpaired in DR32/2 mice. The
abTCR is first expressed at the DP stage, resulting in a pop-
ulation of abTCRlo and CD3lo thymocytes which then undergo
positive selection to generate the abTCRhi and CD3hi SP sub-
sets. Positively selected thymocytes also transiently up-regulate
the expression of CD69. Analysis of CD3 and CD69 expression
on thymocytes from DR3-deficient mice showed no significant
difference in the proportions of CD3hi or CD69-positive cells
between DR3-null mice and their heterozygous littermates,
suggesting that DR3 is not absolutely required for positive
selection (data not shown). This conclusion was consistent with
a flow cytometric analysis of DR3-deficient female mice ex-
pressing the H-Y TCR. No difference was observed in the
numbers or proportions of H-Y TCR-expressing CD8 SP cells
between DR3-expressing or -deficient thymocytes (Table 2).
The H-Y TCR is H-2Kb restricted and therefore selects on
both C57BL/6 and 129 mouse strain backgrounds. Thus, the
mixed strain nature of the knockouts should not affect the
efficiency of positive or negative selection. Taken together,
these results demonstrate that DR3 is not required for positive
selection during thymocyte development.
DISCUSSION
DR3 belongs to a family of receptors that plays an important
role in regulating cell survival and proliferation. These pro-
cesses are tightly regulated during T-cell development. Thus,
signals originating from the pre-TCR mediate the survival and
FIG. 5. Apoptosis of thymocytes and lymphocytes after exposure to
various apoptosis inducing agents. Assays were carried out over 48 h
with apoptosis measured using annexin V-FITC staining or sub-G1
peak following staining with propidium iodide as described in Mate-
rials and Methods. There were no differences in the induction of
apoptosis using cycloheximide and anti-Fas, dexamethasone, or etopo-
side on thymocytes (A) or lymphocytes (B) derived from inguinal
lymph nodes from DR31/1 (open triangles), DR31/2 (closed circles),
or DR32/2 (open circles) mice.
FIG. 6. Proliferation of lymphocytes, thymocytes, and splenocytes
to various stimuli Assays were carried out over 96 h with proliferation
measured by [3H]thymidine uptake over the final 18 to 24 h as de-
scribed in Materials and Methods. There were no significant differ-
ences in thymidine uptake of lymphocytes (top), splenocytes (middle),
or thymocytes (bottom) between DR31/2 and DR32/2 cells using
anti-CD3, anti-CD3, and anti-CD28, PMA and ionomycin, or con-
canavalin A as stimuli. Data are presented as a stimulation index over
medium-only controls, which were not significantly different between
DR31/2 and DR32/2 cells. Filled bars, DR32/2; hatched bars, DR31/1.
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proliferation of pre-T cells that have undergone in-frame
TCRb gene rearrangements. The abTCR controls the survival
of DP thymocytes, selecting those cells expressing TCR with
intermediate affinity for MHC ligand and inducing pro-
grammed cell death of high-affinity, autoreactive T cells. DP
thymocytes that fail to express an abTCR also undergo apo-
ptosis. The expression of DR3 in developing thymocytes
prompted the hypothesis that it is a key regulator of life/death
decisions during thymocyte development. This notion was
tested by generating and analyzing mice deficient in DR3 ex-
pression.
TNFR family members containing death domains (TNFR1,
Fas, DR3, DR4, DR5, and DR6) transduce death signals by
interaction of their death domains with FADD, a death do-
main-containing cytoplasmic protein. FADD then recruits
other cytoplasmic effectors such as caspase 8, TRADD,
TRAF2, and RIP that activate the apoptotic machinery (41).
Studies of transgenic mice expressing DN-FADD in develop-
ing thymocytes have given rise to the hypothesis that stimula-
tion of death domain-containing TNFRs on early pre-T cells
induces cell death via FADD only in the absence of pre-TCR-
derived signals (33). In the presence of pre-TCR-derived sig-
nals, the TNFR signals proliferation. The present study dem-
onstrates that DR3, which is expressed on early and late pre-T
cells, is not essential for the transduction of apoptosis or pro-
liferation signals at the pre-TCR-mediated developmental
checkpoint. It may, however, participate in the regulation of
b-selected thymocytes in concert with other death receptors,
such as DR5, Fas, and TNFR1. An analysis of mice deficient in
the expression of multiple death receptors would resolve this
question.
The DP-to-SP thymocyte transition is associated with exten-
sive cell death. The pathway(s) that, in concert with signals
derived from high-affinity TCRs, induce apoptosis in DP thy-
mocytes have not been defined. TNFRs have, however, been
implicated in negative selection in the thymus. Thus, a role for
Fas in negative selection at high doses of antigen has been
proposed (23). Also, negative selection has been shown to be
either enhanced following CD30 overexpression (9) or par-
tially impaired in mice deficient in the expression of CD30, a
non-death domain-containing member of the TNFR superfam-
ily (2). We show here that DR3 is also important for negative
selection, which is impaired in the absence of this receptor.
Thus, the induction of apoptosis in DP thymocytes by anti-
CD3, an agonist that is presumed to mimic a high-affinity TCR
interaction, is impaired at least at low concentrations of anti-
CD3 (2 and 10 mg/ml) in DR3-null mice. Interestingly, this
effect is abrogated by high anti-CD3 concentrations, suggesting
a greater contribution of DR3 to apoptosis when the signaling
strength is not maximal. Also, the deletion of H-Y TCR trans-
genic thymocytes in male mice is partially inhibited, an effect
which is manifested most clearly in older mice. Although the
numbers and proportions of H-Y TCR transgenic thymocytes
were indistinguishable between DR32/2 and DR31/2 back-
grounds in 6-week-old male mice, a significant inhibition of
negative selection occurred in DR3-null mice at 10 weeks, at 14
weeks, when H-Y TCR-expressing thymocytes were virtually
undetectable in most male mice expressing DR3, transgene-
positive cells were easily detectable in all DR3-null mice ana-
lyzed. However, substantial negative selection had clearly oc-
curred in male DR3-null mice, since at 14 weeks, male
thymuses contained only about 1/100 the numbers of cells
found in the thymuses of female transgenic mice.
The notion that death domain-containing TNFRs play a role
in negative selection is in apparent contradiction to studies of
mice expressing DN-FADD in thymocytes. In one such study,
negative selection was unaffected by DN-FADD, although in
this study negative selection was assayed in 6-week-old H-Y
TCR male mice (50). At this age, we observed no difference in
negative selection in the presence or absence of DR3. In an
independent study, the deletion of autoreactive thymocytes
was enhanced in H-Y TCR1 DN-FADD1 male thymocytes
(34). These studies suggest that FADD signaling does not lead
exclusively to cell death in thymocytes. This, in turn, suggests
that FADD-independent pathways from death domain-con-
taining TNFRs activate caspases in negative selection. Adapter
molecules such as RIP, RAIDD, and Daxx have been shown to
interact with the CD95 death domain, thereby activating a
caspase cascade leading to apoptosis (15, 55). It is possible that
these cytoplasmic signaling molecules also transduce DR3-
mediated signals in thymocytes. A recent study has, however,
failed to support a role for caspase activity in negative selec-
tion. In this study, mice expressing an inhibitor (p35) of
caspase activity in thymocytes showed unimpaired negative
selection (14). However, an independent study, using an iden-
tical strategy, revealed a reduction of negative selection upon
inhibition of caspase activity (21). Therefore, the role of
caspases in thymocyte negative selection remains unresolved.
The observation that DR3-null mice exhibit a partial impair-
ment of negative selection can be interpreted within a model in
which several different surface molecules act in concert to
control the removal of autoreactive thymocytes (23). Accord-
ing to this model, disruption of a single surface receptor or
signal transduction pathway would not be expected to result in
a complete block in negative selection, a prediction that is
observed in practice. The age dependency of the negative se-
lection defect in DR3-null mice in H-Y TCR-transgenic mice
may be due to developmental regulation of the ligand(s) for
DR3 or, alternatively, to the developmental stage at which
deletion occurs in the H-Y TCR model which is likely to be at
the DN stage or in the transition from DN to DP thymocytes.
TABLE 2. Positive selection in female H-Y transgenic DR32/2 and
DR31/2 mice
Organ (cell type) Age(wk)
No. of cells (106 6 SD)a
KO (n) HET (n)
Thymus (all thymocytes) 6 129 6 29 (7) 134 6 42 (10)
10 95 6 29 (7) 98 6 31 (12)
14 74 6 49 (7) 75 6 24 (6)
Thymus (CD81 T3701) 6 33.2 6 12.1 (7) 51.8 6 30.3 (10)
10 25.4 6 7.3 (7) 31.1 6 13.3 (12)
14 24.4 6 10.0 (7) 22.2 6 6.5 (6)
Spleen (CD81 T3701) 6 2.9 6 0.4 (7) 3.3 6 2.1 (10)
10 4.7 6 4.0 (7) 4.8 6 2.1 (12)
14 2.7 6 1.6 (7) 3.2 6 1.7 (6)
Inguinal LN (CD81 T3701) 6 0.38 6 0.21 (7) 0.68 6 0.56 (10)
10 0.39 6 0.16 (7) 0.66 6 0.35 (12)
14 0.73 6 0.52 (7) 0.63 6 0.34 (6)
a In all cases, the difference between KO and HET values was nonsignificant.
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Thus, the relative importance of a particular deletional mech-
anism may vary with age or with the stage of thymocyte devel-
opment at which deletion of a particular TCR occurs.
Despite the impairment of negative selection in DR3-null
mice, there were no signs of autoimmunity in these mice as
indicated by the presence of DNA autoantibodies, nor was
development of autoimmunity significantly accelerated on an
lpr (Fas mutant) background (unpublished data). Further-
more, several other forms of apoptosis were unaffected. There
was no difference in the rate of spontaneous cell death of
thymocytes in culture or of the rate of apoptosis of thymocytes
or T cells after treatment with glucocorticoids, DNA-damaging
agents, or anti-Fas in the presence of protein synthesis inhib-
itors. Moreover, no difference in endogenous superantigen-
mediated deletion of T cells was detected. This observation is
consistent with the analysis of other transgenic models with
defects in negative selection. For example, CD30-null mice (2)
and mice lacking expression of the helix-loop-helix inhibitor
protein Id3 (38) have impaired negative selection, but T cells
specific for endogenous superantigens are efficiently deleted.
Conversely, the antiapoptotic protein Bcl-2 inhibits multiple
forms of apoptosis but not endogenous superantigen-induced
negative selection in thymocytes (43), although bcl-2 transgenic
mice have impaired negative selection when tested on a TCR
transgenic background (45, 54). Taken together with the
present study, these data suggest that there are qualitatively or
quantitatively distinct cell death programs that operate at dif-
ferent stages of T-cell development to ensure effective central
tolerance.
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